abbott

    By Danny King

    | 7:15PM 12/22/2010
    Abbott Laboratories is recalling roughly 359 million blood-sugar test strips for diabetics after the strips turned out to yield falsely low readings.

    By Melly Alazraki

    | 4:14PM 10/08/2010
    Drug and medical-device maker Abbott Laboratories announced Friday that it will voluntarily withdraw its controversial obesity drug Meridia, (sibutramine) from the U.S. market at the request of the FDA, due to concerns it increases the risk of heart attacks and strokes.

    By The Associated Press

    | 10:30PM 9/23/2010
    Abbott has recalled 5 million containers of its top-selling powdered baby formula, Similac, after finding beetles at one of its factories. But parents shouldn't panic, the company says. The chances that any beetlejuice actually made it into the formula is slim, and doctors say babies wouldn't be harmed even if it did.

    By Melly Alazraki

    | 5:00PM 12/15/2009
    Acquisitions and deals are always a risky business, especially in the pharmaceuticals industry. Just today, Elan Corp. (ELN) and Gilead Sciences (GILD) discovered the price of such deals when both halted drug trials on compounds developed by other pharmaceutical firms. Due to safety concerns, Elan...

    By Melly Alazraki

    | 4:40PM 12/01/2009
    The case of Abbott Laboratories' (ABT) cholesterol drug TriCor is quite interesting. The drug has been a blockbuster, and it has been under patent protection for decades. That's right, decades. Now, Abbott has managed to seal a deal with generic-drug maker Teva Pharmaceuticals Industries (TEVA)...

    By Melly Alazraki

    | 10:40AM 9/24/2009
    As the global financial markets stabilize, the world economy starts recovering and stock markets rally, the pharmaceutical sector, too, is heating up with almost daily deal action. On Wednesday, The Wall Street Journal reported Abbott Laboratories (ABT) has joined the bidding for the pharmaceutical...

    By Melly Alazraki

    | 1:30PM 6/30/2009
    Abbott Laboratories (ABT) probably did not want to be the one to break this particular record, but it wasn't up to the big pharmaceutical company. It was up to a jury, and the jury ordered Abbott to pay Johnson & Johnson (JNJ) $1.67 billion for patent infringement of its rheumatoid arthritis...